ECM sulfation as a metabolic sink that drives age‑associated NAD+ decline

Hypothesis

Age‑related increases in chondroitin sulfate sulfation actively consume nucleotide sugars and ATP, creating a metabolic drain that limits NAD+ biosynthesis and thus reduces cellular repair capacity.

Mechanistic rationale

The hexosamine biosynthetic pathway (HBP) supplies UDP‑GlcNAc for both protein O‑GlcNAcylation and glycosaminoglycan (GAG) synthesis. In aged tissue, transcriptional up‑regulation of GAG sulfotransferases (e.g., CHST11 for C6S, CHST3 for C4S) raises flux through the HBP, consuming UDP‑GlcNAc, UTP, acetyl‑CoA and glutamine—substrates that also feed NAD+ salvage (NAMPT uses NAM + ATP → NMN; NAD+ synthetase uses ATP). Each sulfotransferase reaction additionally requires 3′‑phosphoadenosine‑5′‑phosphosulfate (PAPS), which is synthesized from ATP and inorganic sulfate. Consequently, heightened sulfation creates a competing demand for ATP, UTP and amino acids, lowering the pool available for NAD+ production. This reframes NAD+ decline not as a passive loss but as a consequence of the cell’s budget being re‑allocated to an actively remodeled extracellular matrix.

Novel prediction

If sulfation-driven metabolite consumption is causal, then pharmacological or genetic inhibition of key chondroitin sulfate sulfotransferases in aged organisms will restore NAD+ levels independent of changes in NAD+ precursor supplementation.

Experimental design

1. Model: 24‑month‑old mice (both sexes) exhibiting the brain C4S↑/C6S↓ shift and cardiac HBP activation reported in et al.
2. Intervention:
   • Pharmacological: systemic delivery of a selective CHST11 inhibitor (e.g., compound 5‑O‑methyl‑ flavonoids shown to block C6S transfer) or low‑dose sodium chlorate to globally inhibit sulfotransferase activity.
   • Genetic: AAV‑mediated CRISPR‑Cas9 knockout of Chst11 specifically in astrocytes or cardiomyocytes.
3. Controls: age‑matched vehicle‑treated mice and young (3‑month) mice.
4. Readouts (after 4 weeks):
   • ECM sulfation composition by LC‑MS disaccharide analysis (C4S/C6S ratio).
   • Tissue NAD+ and NADH concentrations (enzymatic cycling assay).
   • HBP flux via UDP‑GlcNAc levels (mass spectrometry).
   • Functional assays: axonal outgrowth ex vivo from hippocampal slices; cardiac oxygen consumption rate (Seahorse).
5. Statistical plan: n=8 per group; two‑way ANOVA with factors age and treatment; significance set at p<0.05.

Expected outcomes and falsifiability

• Supporting outcome: sulfotransferase inhibition reduces C6S (or total sulfation) by ≥30%, raises NAD+ levels to ≥80% of young values, and improves axonal growth or cardiac respiration without exogenous NAD+ precursors.
• Falsifying outcome: despite significant reduction in GAG sulfation, NAD+ levels remain unchanged relative to vehicle‑treated aged mice, indicating that sulfation does not substantially drain NAD+ precursors.

Such a result would directly test whether the ECM remodeling described by et al. is a driver rather than a biomarker of metabolic decline, linking the "ambition downgrade" concept to a concrete, targetable biochemical sink.